NEW YORK, July 29, 2026, 08:04 EDT — U.S. equity markets traded ahead of the opening bell.
- CMS plans to discontinue temporary Part D assistance following 2026. This year, the program’s expenditure totaled $3.6 billion.
- Initial 2027 bids are up 23.7%, and the base beneficiary premium climbs 6%.
- Centene NYSE:CNC accounts for 35% of stand-alone Part D enrollees.
The Trump administration plans to discontinue temporary assistance for stand-alone prescription drug plans, or PDPs, following 2026. Insurers will assume increased pricing risk starting next year as a result.
This does not leave a direct $3.6 billion earnings gap. Funds reduced premiums for beneficiaries, and insurers are able to adjust rates or benefits. The more difficult issue is determining which companies lose enrollees.
According to initial 2027 figures from CMS, the national average monthly bid stands at $296.05, marking a 23.7% increase from 2026. The standard beneficiary premium climbs 6% to $41.33.
The margin indicates that ongoing federal subsidies continue to account for a significant portion of the increased bid values. However, the additional PDP-targeted buffer is no longer present.
KFF estimated the buffer at $16 per member each month in 2026. Medicare Advantage prescription drug plans (MA-PDs) applied a $53 monthly offset sourced from rebates. That gap may increase further.
The average 2026 PDP premium stood at $36, compared with $8 for MA-PDs. This 4.5-fold difference already prompts consumers to compare plans. Rising PDP prices may further drive movement toward Medicare Advantage.
According to KFF enrollment data, there are significant differences in PDP exposure compared to MA-PD offsets.
| Listed insurer | 2026 stand-alone PDP position | PDP enrollment trend | MA-PD offset |
|---|---|---|---|
| Centene NYSE:CNC | 35%; 8.7 million | Risen 11% | Not among top-three sponsors |
| CVS Health NYSE:CVS | 16% | Decreased | 10% share of market |
| UnitedHealth Group NYSE:UNH | 15% | Slight growth | 26% share of market |
| Humana NYSE:HUM | 3.7 million | Risen 61% | 20% share of market |
Centene leads its closest publicly traded competitor in PDP market share by 19 percentage points. In contrast to UnitedHealth, Humana, and CVS, Centene does not hold a top-three position in the MA-PD segment. Consequently, its member retention relies more heavily on PDP pricing.
Centene’s yearly report spells out this sensitivity. According to the report, a large portion of PDP membership is due to automatic assignments, which rely on bids remaining under regional benchmarks.
All 34 regional benchmarks were cleared by its 2026 bids. Membership subsequently rose 11% to reach 8.7 million. Centene cautioned that failure to maintain benchmark status could have a significant impact on revenue.
As a result, the subsidy rollback intensifies Centene’s dilemma. The company can either keep premiums low to maintain enrollment numbers, or choose to safeguard margins, which may lead to a decline in member count.
Humana faces ongoing exposure to new pricing adjustments. The company’s PDP enrollment surged 61% as premiums declined in numerous regions. Its 20% share in MA-PD offers increased offsetting strength.
UnitedHealth leads with the largest MA-PD offset, maintaining a 26% share of the market. CVS presents a more even distribution, accounting for 16% of PDPs and 10% of MA-PDs.
CMS Administrator Mehmet Oz stated that “Premiums will go up by less than $10 for most Medicare recipients,” with some potentially seeing lower amounts. KFF’s Juliette Cubanski cautioned that certain individuals might experience “relatively steep” increases. Reuters
Insurers were continuing to assess the decision on Tuesday night, according to industry group AHIP. Updated premiums and available plans are expected in mid-to-late September. The full impact on earnings has not been determined.
The primary threat to this thesis comes from how insurers act. Companies could choose to operate with slimmer margins or adjust products to reduce customer turnover. Critical data on county-level premiums and benchmark standings is still unavailable.
September pricing files will distinguish between a margin squeeze and an enrollment transfer. Centene’s regional benchmark standings will offer the first clear indication.
